Effectiveness of bromocriptine in the treatment of autoimmune diseases

NeuroImmune Biology

Volumn 2, Issue C, 2002, Pages 287-296

  Walker, Sara E ^a  

^a UNIVERSITY OF MISSOURI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77957098966     PISSN: 15677443     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1567-7443(02)80024-2     Document Type: Article

References (52)

1. Russell D.H. New aspects of prolactin and immunity: a lymphocyte-derived prolactin-like product and nuclear protein kinase C activation. Trends Pharmacol Sci 10 (1989) 40-44
2. Berczi I., Nagy E., de Toledo S.M., Matusik R.J., and Friesen H.G. Pituitary hormones regulate c-myc and DNA synthesis in lymphoid tissue. J Immunol 146 (1990) 2201-2206
3. Thoreau E., Petridou B., Kelly P.A., Djiane J., and Mornon J.P. Structural symmetry of the extracellular domain of the cytokine/growth hormone/prolactin receptor family and interferon receptors revealed by hydrophobic cluster analysis. FEBS Letters 282 (1991) 26-31
4. Yu-Lee L.-Y. Molecular actions of prolactin in the immune system. Proc Soc Exp Biol Med 215 (1997) 35-52
5. Russell D.H., Kibler R., Matrisian L., Larson D.F., Boulos B., and Magun B.E. Prolactin receptors on human T and B lymphocytes: Antagonism to prolactin binding by cyclosporine. J Immunol 134 (1985) 3027-3031
6. Pellegrini I., Lebrun J., Ali S., and Kelly P.A. Expression of prolactin and its receptor in human lymphoid cells. Molec Endocrinol 6 (1992) 1023
7. Dardenne M., Kelly P.A., Bach J., and Savino W. Identification and functional activity of prolactin receptors in thymic epithelial cells. Proc Natl Acad Sci USA 88 (1991) 9700-9704
8. Walker S.E., McMurray R.W., Houri J.M., Allen S.H., Keisler D., Sharp G.C., and Schlechte J.A. Effects of prolactin in stimulating disease activity in systemic lupus erythematosus. Proc NY Acad Sci 840 (1998) 762-772
9. Parkes D. Bromocriptine. N Engl J Med 301 (1979) 873-878
10. Vance M.L., Evans W.S., and Thorner M.O. Bromocriptine. Diagnosis and treatment. Drugs five years later. Ann Intern Med 100 (1984) 78-91
11. Larrazet F., Spaulding C., Lobreau H.J., Weber S., and Guerin F. Possible bromocriptine-induced myocardial infarction. Ann Intern Med 118 (1993) 199-200
12. Katz M., Kroll D., Pak I., Osimoni A., and Hirsch M. Puerperal hypertension, stroke, and seizures after suppression of lactation with bromocriptine. Obstet Gynecol 66 (1985) 822-824
13. McElvaney N.G., Wilcox P.G., Churg A., and Fleetham J.A. Pleuropulmonary disease during bromocriptine treatment of Parkinson's disease. Arch Intern Med 148 (1988) 2231-2236
14. Kinnunen E., and Viljanen A. Pleuropulmonary involvement during bromocriptine treatment. Chest 94 (1988) 1034-1036
15. Hiestand P.C., Mekler P., Nordmann R., Greider A., and Permmangkol C. Prolactin as a modulator of lymphocyte responsiveness provides a possible mechanism of action for cyclosporine. Proc Natl Acad Sci USA 83 (1986) 2599-2603
16. Nagy E., Berczi I., Wren G.E., Asas S.L., and Kovacs K. Immunomodulation by bromocriptine. Immunopharmacology 6 (1983) 231-243
17. Bernton E.W., Meltzer M.S., and Holaday J.W. Suppression of macrophage activation and T-lymphocyte function in hypoproalctinemic mice. Science 239 (1988) 401-404
18. Morikawa K., Oseko F., and Morikawa S. Immunosuppressive property of bromocriptine on human B lymphocyte function in vitro. Clin Exp Immunol 93 (1993) 200-205
19. Morikawa K., Oseko F., and Morikawa S. Immunosuppressive activity of bromocriptine on human T lymphocyte function in vitro. Clin Exp Immunol 95 (1994) 514-518
20. Neidhart M. Bromocriptine has little direct effect on murine lymphocytes, the immunomodulatory effect being mediated by the suppression of prolactin secretion. Biomed & Pharmacother 51 (1997) 118-125
21. Palestine A.G., Muellenberg-Coulombre C.G., Kim M.K., Gelato M.C., and Nussenblatt R.B. Bromocriptine and low dose cyclosporine in the treatment of experimental autoimmune uveitis in the rat. J Clin Invest 79 (1987) 1078-1081
22. Neidhart M. Synergism between long-acting bromocryptine microcapsules and cyclosporine A in the prevention of various autoimmune diseases in rats. Experientia 52 (1996) 892-899
23. Riskind P.N., Massacesi L., Doolittle T.H., and Hauser S.L. The role of prolactin in autoimmune demyelination: Suppression of experimental allergic encephalomyelitis by bromocriptine. Ann Neurol 29 (1991) 542-547
24. Berczi B., Nagy E., Asa S.L., and Kovacs K. The influence of pituitary hormones on adjuvant arthritis. Arthritis Rheum 27 (1984) 682-688
25. Neidhart M. Bromocriptine microcapsules inhibit ornithine decarboxylase activity induced by Freund's complete adjuvant in lymphoid tissues of male rats. Endocrinology 125 (1989) 2846-2852
26. Dijkstra C.D., Rouppe van der Voort E., De Groot C., Uitdehaag B.M.J., Polman C.H., and Berkenbosch F. The therapeutic effect of bromocriptine on acute and chronic experimental allergic encephalomyelitis. Ann Neurol 31 (1992) 450-451
27. 2-dopamine agonist bromocriptine on acute and relapsing experimental allergic encephalomyelitis. Psychoneuroendocrinology 19 (1994) 135-142
28. Blank M., Karuae I., Buskila D., et al. Bromocriptine immunomodulation of experimental SLE and primary anti-phospholipid syndrome via induction of nonspecific T suppressor cells. Cell Immunol 162 (1995) 114-122
29. Mahon J.L., Gunn H.C., Stobie K., Gibson C., Garcia B., Dupre J., and Stiller C.R. The effect of bromocriptine and cyclosporine on spontaneous diabetes in BB rats. Transplant Proc 20 spppl (1998) 197-200
30. Hawkins T.A., Gala R.R., and Dunbar J.C. Prolactin modulates the incidence of diabetes in male and female NOD mice. Autoimmunity 18 (1994) 155-162
31. Durant S., Alves V., Coulaud J., El Hasnaoui A., Dardenne M., and Homo-Delarche F. Attempts to pharmacologically modulate prolactin levels and type 1 autoimmune diabetes in the nonobes diabetic (NOD) mouse. J Autoimmunol 8 (1995) 875-885
32. McMurray R., Keisler D., Kanuckel K., Izui S., and Walker S.E. Prolactin influences autoimmune disease activity in the female B/W mouse. J Immunol 147 (1991) 3780-3787
33. Elbourne K.B., Keisler D., and McMurray R.W. Differential effects of estrogen and prolactin on autoimmune disease in the NZB/NZW F1 mouse model of systemic lupus erythematosus. Lupus 7 (1998) 420-427
34. Neidhart M. Bromocriptine has little direct effect on murine lymphocytes, the immunomodulatory effect being mediated by the suppression of prolactin secretion. Biomed & Pharmacother 51 (1997) 118-125
35. Hedner L.P., and Bynke G. Endogenous iridocyclitis relieved during treatment with bromocriptine. Amer J Ophthalmol 100 (1985) 618-619
36. Palestine A.G., Nussenblatt R.B., and Gelato M. Therapy for human autoimmune uveitis with low-dose cyclosporine plus bromocriptine. Transpl Proc 20 (1988) 131-135
37. Schaaf L., Zierhut M., Baur E.M., et al. Bromocriptine in patients with chronic autoimmune-associated disorders. Klin Wochenschr 69 (1991) 943
38. Bravo G., Zazueta B., and Lavalle C. An acute remission of Reiter's syndrome in male patients treated with bromocriptine. J Rheumatol 19 (1992) 747-750
39. Pijl H., Ohashi S., Matsuda M., et al. Bromocriptine: a novel approach to the treatment of type 2 diabetes. Diabetes Care 23 (2000) 1154-1161
40. Wasada T., Kawahara R., and Iwamoto Y. Lack of evidence for bromocriptine effect on glucose tolerance, insulin resistance, and body fat stores in obese type 2 diabetic patients. Diabetes Care 23 (2000) 1040
41. Atkison P.R., Mahon J.L., Dupre J., et al. Interaction of bromocriptine and cyclosporine in insulin dependent diabetes mellitus: results from the Canadian open study. J Autoimmun 3 (1990) 793-797
42. Draca S., and Levic Z. The possible role of prolactin in the immunopathogenesis of multiple sclerosis. Medical Hypotheses 47 (1996) 89-92
43. Bissay V., De Klippel N., Herroelen L., et al. Bromocriptine therapy in multiple sclerosis: an open label pilot study. Clin Neuropharmacol 17 (1994) 473-476
44. Figueroa F.E., Carrion F., Martinez M.E., et al. Bromocriptine induces immunological changes related to disease parameters in rheumatoid arthritis. Br J Rheumatol 36 (1997) 1022-1023
45. Finkelstein J.S., Whitcomb R.W., Longcope C., et al. Sex steroid control of gonadotropin secretion in the human male. I. Effects of testosterone administration in normal and gonadotropin-releasing hormone-deficient men. J Clin Endocrinol Metab 73 (1991) 609-620
46. (abstract). Rabiniovich C.E., Schanberg L.E., and Kredich D.W. Intravenous immunoglobulin and bromocriptine in the treatment of refractory neuropsychiatric systemic lupus erythematosus. Arthritis Rheum 33 Suppl. (1990) R22
47. McMurray R.W., Allen S.H., Braun A.L., Rodriguez F., and Walker S.E. Longstanding hyperprolactinemia associated with systemic lupus erythematosus: Possible hormonal stimulation of an autoimmune disease. J Rheumatol 21 (1994) 843-850
48. Funauchi M., Ikoma S., Enomoto H., et al. Prolactin modulates the disease activity of systemic lupus erythematosus accompanied by prolactinoma. Clin Exp Rheumatol 16 (1998) 479-482
49. McMurray R.W., Weidensaul D., Allen S.H., and Walker S.E. Efficacy of bromocriptine in an open label therapeutic trial for systemic lupus erythematosus. J Rheumatol 22 (1995) 2084-2091
50. Walker S.E., Smarr K.L., Parker J.C., Weidensaul D.N., Nelson W., and McMurray R.W. Mood states and disease activity in paitents with systemic lupus erythematosus treated with bromocriptine. Lupus 9 (2000) 527-533
51. Alvarez-Nemeguei J., Cobarrubias-Cobbs A., Escalante-Triay F., Sosa-Munoz J., Miranda J.M., and Jara L.J. Bromocriptine in systemic lupus erythematosus: A double-blind, randomized, placebo-controlled study. Lupus 7 (1998) 414-419
52. (abstract). Walker S.E., Reddy G.H., Miller D., et al. Treatment of active systemic lupus erythematosus (SLE) with the prolactin (PRL) lowering drug, bromocriptine (BC): Comparison with hydroxychloroque (HC) in a randomized, blinded one-year study. Arthritis Rheum 42 (1999) 282